The Pharma M&A Digital Due Diligence Checklist

Why Pharma M&A Digital DD Needs Its Own Checklist

Generic enterprise M&A digital due diligence focuses on technology stack assessment, integration complexity, cybersecurity posture, and technology cost. These are all relevant in pharma deals but they are not sufficient. Pharma deals add several dimensions that generic checklists either do not address or address inadequately.

First, validated systems. Pharma operations run on systems that are validated against 21 CFR Part 11, GAMP 5, and related frameworks. The state of validation across the target’s system inventory is a direct input to post-close compliance risk, and the cost of remediating inadequately validated systems is often a material item. Acquirers that do not specifically diligence validation health surface this issue post-close, sometimes after a regulatory inspection has produced findings.

Second, data integrity. The ALCOA+ data integrity expectations apply across pharma operations and have been the subject of many high-profile warning letters over the past decade. The target’s data integrity posture — including audit trail completeness, change control discipline, and computerized system validation — is a direct input to post-close compliance liability.

Third, AI assets. AI use in pharma has grown rapidly enough that most Series B and beyond pharma companies now have meaningful AI assets, ranging from drug discovery models to manufacturing optimization to clinical operations tools. The inventory, governance, and validation status of these AI assets is a dimension that generic checklists do not address, and the asymmetry between what targets disclose and what acquirers discover post-close is often substantial.

Fourth, regulatory inspection history. The target’s history of FDA, EMA, MHRA, and other regulator inspections, including the technology-related findings, is a window into how rigorous the target’s technology operations actually are. Targets with clean inspection histories are not always rigorous, but targets with histories of repeated technology-related findings almost always have systemic issues that will become acquirer issues post-close.

The pharma-specific checklist addresses these dimensions deliberately. The PwC pharmaceuticals and life sciences practice has documented the cost asymmetry between generic and pharma-specific due diligence across multiple deals in recent years.

Workstream 1: Validated Systems Inventory and Health

The validated systems workstream covers the target’s inventory of systems subject to validation requirements (typically GxP systems), the current state of validation across that inventory, and the change control practices that maintain validation over time.

Questions to ask. What is the complete list of GxP systems, including version, vendor, business owner, and validation status? When was each system last validated, and what was the scope of that validation? What is the change control process, and how many open changes are in flight that may affect validation? What is the periodic review cadence, and what was the most recent periodic review’s finding? What computerized system validation methodology is used (GAMP 5, internal extensions, vendor-led validation), and how is it documented?

Artifacts to request. The validated systems inventory itself, including the system-level validation status. The validation master plan. The most recent periodic reviews for the top 10 to 20 systems by criticality. The change control log for the past 24 months, filtered to changes affecting validated systems. The CSV SOPs. Any audit findings from internal QA or external auditors that addressed validation health.

Failure modes to watch for. Validation inventories that are out of date (the most common pattern), systems that are technically deployed but whose validation status is “in remediation,” large change control backlogs that have not been processed, and CSV practices that exist on paper but are not actually executed in operations. Acquirers that surface any of these patterns should adjust both the price (to reflect the remediation cost) and the integration timeline (to reflect the additional work).

Workstream 2: Data Integrity Posture

Data integrity is the second workstream because the FDA, EMA, and other regulators treat it as central to pharma compliance, and findings in this area can cascade into broader regulatory consequences.

Questions to ask. What ALCOA+ principles are explicitly documented in QMS procedures? What audit trail capabilities exist across critical GxP systems, and where are the gaps? What has been the data integrity finding history (internal QA, external audits, regulatory inspections) over the past five years? Are there any data integrity remediation programs in flight, and what is their status? Are there any patterns of metadata loss, audit trail disablement, or other red flags?

Artifacts to request. The data integrity policy and supporting procedures. The internal audit reports addressing data integrity in the past three years. The 483s, EIRs, and warning letters from regulatory inspections, with technology-related findings highlighted. The list of any open or recently closed data integrity remediation programs. The most recent data integrity assessment of the top 10 to 20 GxP systems.

Failure modes to watch for. Patterns of audit trail issues that have been remediated repeatedly without addressing root cause. Reliance on procedural controls in environments where technical controls would be feasible. Findings that suggest tampering or deliberate non-compliance (rare but extremely material when present). Data integrity programs that exist on paper but lack operational depth. Any of these patterns should prompt acquirer caution, and material findings can be deal-breakers.

Workstream 3: Cybersecurity and Third-Party Risk

Cybersecurity diligence in pharma covers what generic enterprise diligence covers (NIST CSF posture, recent incidents, third-party risk programs) plus pharma-specific dimensions (validated system protections, regulatory cyber expectations, GxP-relevant third-party assessments).

Questions to ask. What cybersecurity framework is the company aligned to, and what is the most recent self-assessment or external assessment? What incidents have occurred in the past five years, what was the impact, and what was the remediation? What is the third-party risk program, and how is it executed for GxP-relevant vendors? Are there pending or recent regulatory engagements specifically on cyber posture? What is the cyber insurance status, and what exclusions apply?

Artifacts to request. Recent cybersecurity assessments, including penetration tests, vulnerability assessments, and any external audits. The incident history with material incidents documented. The third-party risk program documentation, including the inventory of high-risk vendors and their assessment status. The cyber insurance policy and any recent renewal correspondence highlighting changes.

Failure modes to watch for. Cybersecurity programs that are framework-aligned in documentation but are not actually executed at the operational depth required. Material incidents that were not reported publicly or that have unresolved residual risk. Third-party risk programs that exclude GxP-relevant vendors because they are not categorized as IT. Cyber insurance that excludes the specific exposures most likely to manifest in pharma operations.

Workstream 4: AI Asset Inventory and Governance

AI asset diligence is the newest workstream and the one where acquirer practice is least mature. The dimensions to address are well-defined even if the diligence practices around them are still developing.

Questions to ask. What is the complete inventory of AI/ML models in production use, including the use case, the data they train on, the validation status, and the operational owner? What AI governance framework is in place, and how is it executed? Which AI use cases touch GxP-relevant workflows, and how are they validated? What is the inventory of vendor-embedded AI in platform tools (MES, LIMS, EMS, ELN), and how is it governed? Are there any AI-related findings from internal QA or external audits?

Artifacts to request. The AI asset inventory. The AI governance framework documentation. The validation packages for the top five AI use cases by GxP relevance. The vendor list and the AI capabilities embedded in each. Any internal or external audit findings on AI use.

Failure modes to watch for. AI inventories that are incomplete (extremely common). AI governance frameworks that exist on paper but are not actually executed. GxP-touching AI use cases that have not been validated under the credibility framework or equivalent. Vendor-embedded AI that has not been brought into the governance framework. AI development practices that produce models without documented validation or change control. Acquirers should expect this workstream to surface meaningful gaps in most pharma targets, and should budget for substantial post-close remediation work.

Workstream 5: Platform Architecture and Technical Debt

Platform architecture diligence covers the foundational systems on which the target’s operations run, and the technical debt that has accumulated in those systems over time.

The discipline is to identify both the platforms themselves and the technical debt within each platform. Targets routinely run platforms that are technically current but heavily customized in ways that complicate upgrades, integration, and change. The diligence should surface this customization explicitly, because it materially affects integration cost.

Workstream 6: Vendor Concentration and Contracts

Vendor concentration diligence covers the target’s exposure to specific vendors, the contractual terms that govern those relationships, and the change-of-control provisions that may activate at close.

Questions to ask. What is the spend by vendor across IT and digital? Which vendors represent more than 5 percent of total IT spend? What are the change-of-control provisions in major vendor contracts? What are the renewal timelines for the top 20 vendor contracts? Are there any contracts under active dispute or negotiation? What is the vendor consolidation history (which vendors have been added or removed in the past three years)?

Artifacts to request. The full vendor list with annual spend. The contracts for the top 20 vendors by spend, with change-of-control provisions highlighted. The renewal schedule for the next 24 months. The vendor management policy. Any active vendor disputes or material renegotiations.

Failure modes to watch for. Material vendor concentration that the acquirer does not have a corresponding relationship with, creating either dependency risk or duplicative spend post-close. Change-of-control provisions that allow vendors to renegotiate at close, often producing material cost increases. Contracts approaching renewal during the deal timeline that may be used by vendors as leverage. The Deloitte life sciences M&A coverage has documented this pattern across multiple recent pharma deals.

Workstream 7: People, Skills, and Knowledge

The people workstream covers the technology and digital talent inside the target, the knowledge concentration, and the post-close retention risk.

Questions to ask. What is the organization chart for IT, data, AI, and adjacent functions? Who are the key technical leaders, and what is their tenure, comp, and retention risk? Where is critical knowledge concentrated in individuals versus documented? What is the contractor and consultant dependency, and which knowledge sits in those relationships? What is the post-close retention plan being signaled, and what gaps will need to be filled?

Artifacts to request. Organization charts for digital functions. Tenure and comp data for key roles (within the limits of what diligence can typically obtain). Knowledge management documentation, including system runbooks, validation procedure ownership, and SOP authorship. The contractor and consultant inventory with scope and tenure.

Failure modes to watch for. Knowledge concentrated in individuals who are unlikely to remain post-close. Heavy contractor dependency in critical operations that will not transfer cleanly. Comp gaps between target and acquirer that will trigger retention costs at close. Documentation gaps that will leave the acquirer without the knowledge needed to operate the inherited systems.

Workstream 8: Integration Cost Modeling

The integration cost workstream synthesizes the findings from the prior seven workstreams into a defensible cost estimate for post-close integration. The discipline is to be specific about what is being modeled and to build the estimate from operationally concrete inputs rather than from generic per-headcount or per-revenue benchmarks.

Categories to model. Validated system remediation cost (driven by workstream 1 findings). Data integrity remediation cost (workstream 2). Cybersecurity remediation cost (workstream 3). AI governance remediation cost (workstream 4). Platform consolidation cost (workstream 5). Vendor consolidation cost (workstream 6). Talent retention and recruitment cost (workstream 7). Direct integration project cost (program management, system integration, change management).

The total estimate should be expressed as a range with named drivers, not as a point estimate. Boards and deal teams that are accustomed to point estimates will push back, but the honest answer is that integration cost in pharma has wide variance driven by what surfaces during execution, and a range with drivers is more useful than a point that will be wrong. The BCG biopharmaceuticals practice has published industry-aggregate integration cost benchmarks that can be referenced for sanity-checking, though specific deal modeling should not be driven by benchmarks alone.

Putting it together: the workstream sequence and timing

The eight workstreams are not run in parallel. In practice, the sequence is roughly: vendor concentration, platform architecture, and validated systems first (because they shape what the integration is); then data integrity, cybersecurity, and AI assets (because they shape the compliance and risk picture); then people and integration cost (because they synthesize the prior work). A six-week to eight-week diligence window is typical for a mid-size pharma deal, with the workstreams overlapping in the middle weeks.

The output of the diligence is the digital due diligence report, which should be structured around the same eight workstreams and should be readable by deal team members who are not digital specialists. Findings should be categorized as deal-breakers, material price impacts, integration cost adjustments, and post-close watch items. Recommendations should be specific enough that the acquirer’s post-close integration team can pick them up and execute against them.

The pharma-specific digital due diligence checklist is materially more involved than generic enterprise checklists, and the work required is correspondingly larger. The payoff is that the deals run through it consistently surface integration cost and compliance liability that would have manifested post-close in much more disruptive and expensive forms. Acquirers that invest in this workstream during diligence routinely produce post-close integration experiences that are materially smoother than acquirers that do not, and the cumulative effect across a portfolio of deals is substantial.

References & Sources